恢复试验数据表明罗氏关节炎药物可减少住院的COVID-19患者的死亡
罗氏关节炎药物Tocilizumab
降低了严重COVID-19住院患者的死亡风险，
根据上周四发布的结果，这还缩短了恢复时间并减少了机械通风的需求。
调查结果
—来自英国的RECOVERY试验，该试验自2020年3月以来一直在测试COVID-19的一系列潜在治疗方法—
在最近一系列的混合试验结果之后，应该有助于消除关于妥珠单抗对COVID-19患者是否有任何益处的困惑。
Tocilizumab reduces deaths in patients hospitalised with COVID-19
The RECOVERY trial
has been testing a range of potential treatments for COVID-19 since March 2020.
Tocilizumab, an intravenous drug used to treat rheumatoid arthritis,
was added to the trial in April 2020 for patients with COVID-19 who required oxygen and had evidence of inflammation.
Recruitment to the tocilizumab arm stopped on 24 January 2021 since, in the view of the trial Steering Committee,
sufficient patients had been enrolled to establish whether or not the drug had a meaningful benefit.
A total of 2022 patients were randomly allocated to receive tocilizumab by intravenous infusion and were compared with 2094 patients randomly allocated to usual care alone.
82% of patients were taking a systemic steroid such as dexamethasone.
Treatment with tocilizumab
significantly reduced deaths: 596 (29%) of the patients in the tocilizumab group died within 28 days compared with 694 (33%) patients in the usual care group (rate ratio 0·86; [95% confidence interval [CI] 0·77 to 0·96]; p=0·007),
an absolute difference of 4%.
This means that for every 25 patients treated with tocilizumab, one additional life would be saved.
RECOVERY Trial
https://www.recoverytrial.net/news/tocilizumab-reduces-deaths-in-patients-hospitalised-with-covid-19